Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Acasti Pharma, Inc. (OTC: ACST).

Full DD Report for ACST

Recent News from (OTC: ACST)

Acasti Pharma Prices $10 Million Underwritten Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, April 24, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that, in connection with its...
Source: GlobeNewswire
Date: April, 24 2018 12:17
Acasti Pharma Announces Overnight Marketed Public Unit Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. Laval, QUEBEC, April 23, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “ Company ” or “ Acasti ”) is pleased to announce that it has filed a prelimi...
Source: GlobeNewswire
Date: April, 23 2018 16:10
Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia
LAVAL, QUÉBEC--(Marketwired - March 14, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre® (omega-3 phospholipid) for the treatment of...
Source: Marketwired
Date: March, 14 2018 08:00
Acasti Pharma Reports Third Quarter FY 2018 Financial Results
LAVAL, QUÉBEC--(Marketwired - Feb. 13, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: Marketwired
Date: February, 13 2018 17:00
Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares
LAVAL, QUÉBEC--(Marketwired - Jan. 22, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: Marketwired
Date: January, 22 2018 17:05
Acasti Pharma Announces Change to Board of Directors
LAVAL, QUÉBEC--(Marketwired - Jan. 16, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Source: Marketwired
Date: January, 16 2018 08:00
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered ...
Source: SeekingAlpha
Date: January, 09 2018 11:02
Premarket Gainers as of 9:05 am
CNIT +63%  on ad terminal sale . More news on: China Information Technology, ChinaCache International, China Commercial Credit, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: January, 05 2018 09:21
Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada
LAVAL, QUÉBEC--(Marketwired - Jan. 4, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment ...
Source: Marketwired
Date: January, 04 2018 08:00
Dawson James Securities Announces Closing of US $10 Million Firm Commitment Offering of Common Shares and Warrants for Acasti Pharma Inc.
BOCA RATON, FL / ACCESSWIRE / January 2, 2018 / Dawson James Securities, Inc., in conjunction with Acasti Pharma Inc. (NASDAQ: ACST; TSX-V: ACST), completed an underwritten offering of 9,900,990 common shares together with warrants to purchase an aggregate of 9,802,935 common shares (includi...
Source: ACCESSWIRE
Date: January, 02 2018 17:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-260.780.770.780.76126,309
2018-04-250.800.780.80990.77363,504
2018-04-240.900.770.9180.75091,464,840
2018-04-231.021.021.03520.999887,245
2018-04-221.061.011.07321.00188,507

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About Acasti Pharma, Inc. (OTC: ACST)

Logo for Acasti Pharma, Inc. (OTC: ACST)

Not available

 

Contact Information

 

 

Current Management

  • Henri Harland / CEO, President
  • Andre Godin / CFO

Current Share Structure

  • Market Cap: $10,979,839 - 03/20/2018
  • Issue and Outstanding: 10,712,038 - 02/29/2016

 


Recent Filings from (OTC: ACST)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 14 2018
Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: March, 06 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: February, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 22 2018

 

 


Daily Technical Chart for (OTC: ACST)

Daily Technical Chart for (OTC: ACST)


Stay tuned for daily updates and more on (OTC: ACST)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ACST)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACST is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ACST and does not buy, sell, or trade any shares of ACST. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us